Landgren A, Bilberg A, Eliasson B, Torres L, Dehlin M, Jacobsson L
Adv Rheumatol. 2025; 65(1):13.
PMID: 40087727
DOI: 10.1186/s42358-025-00444-9.
Coppers B, Heinrich S, Tascilar K, Phutane U, Kleyer A, Simon D
Sci Rep. 2025; 15(1):6018.
PMID: 39972020
PMC: 11840059.
DOI: 10.1038/s41598-025-90295-7.
Cagnotto G, Bruschettini M, Strozyk A, Scire C, Compagno M
Cochrane Database Syst Rev. 2025; 2:CD013614.
PMID: 39945386
PMC: 11822884.
DOI: 10.1002/14651858.CD013614.pub2.
Lindgren L, Thomsen T, Hetland M, Aadahl M, Kristensen S, de Thurah A
Pilot Feasibility Stud. 2025; 11(1):15.
PMID: 39934926
PMC: 11817759.
DOI: 10.1186/s40814-025-01601-z.
Hammam N, El-Hadidi T, El-Hadidi K, Elsaman A, El-Bakry S, Nassr M
Clin Rheumatol. 2025; 44(3):979-988.
PMID: 39913010
PMC: 11865098.
DOI: 10.1007/s10067-025-07356-5.
Peripheral magnetic stimulation for the treatment of fibromyalgia: a systematic review and meta-analysis.
Leenus A, Rahman R, Dana E, Tran C, Westwood D, Osokin E
Pain Manag. 2025; 15(1):45-53.
PMID: 39885680
PMC: 11801343.
DOI: 10.1080/17581869.2025.2459594.
PtpA protein from Mycobacterium avium subsp. paratuberculosis as a potential marker of rheumatoid arthritis in humans.
Hernandez-Bello J, Bach H, Cerpa-Cruz S, Sanchez-Zuno G, Hernandez-Gutierrez R, Nicoletti F
PLoS One. 2025; 20(1):e0316727.
PMID: 39752467
PMC: 11698356.
DOI: 10.1371/journal.pone.0316727.
Health-related quality of life profiles in patients with rheumatoid arthritis: a latent profile analysis.
Song Y, Chen Y, Wen L, He B, Ding Y, Liu M
Front Public Health. 2025; 12:1478376.
PMID: 39744379
PMC: 11688321.
DOI: 10.3389/fpubh.2024.1478376.
The impact of psoriatic arthritis on quality of life: a systematic review.
James L, Hailey L, Suribhatla R, McGagh D, Amarnani R, Bundy C
Ther Adv Musculoskelet Dis. 2024; 16:1759720X241295920.
PMID: 39717741
PMC: 11664531.
DOI: 10.1177/1759720X241295920.
Utility of the GerdQ questionnaire in detecting gastroesophageal symptoms with RA patients.
Nozaki Y, Kishimoto K, Tomita D, Itami T, Ashida C, Kinoshita K
BMC Rheumatol. 2024; 8(1):73.
PMID: 39716318
PMC: 11664924.
DOI: 10.1186/s41927-024-00442-2.
Psychological features of systemic sclerosis: results from an observational study.
Romanazzo S, Rometsch C, Marangoni A, Guiducci S, Cosci F
Front Med (Lausanne). 2024; 11:1473587.
PMID: 39712185
PMC: 11658978.
DOI: 10.3389/fmed.2024.1473587.
Dose reduction and discontinuation of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) for people with psoriatic arthritis in remission or low disease activity.
Ramsay H, Johnston R, Cyril S, Glennon V, Grobler L, Burgess D
Cochrane Database Syst Rev. 2024; 12():CD015880.
PMID: 39679815
PMC: 11648595.
DOI: 10.1002/14651858.CD015880.
Proposal of a radiation-free screening protocol for early detection of interstitial lung involvement in seropositive and ACPA-positive rheumatoid arthritis.
Reichenberger F, Popp F, Hoffmann M, Fischinger C, von Wulffen W, Kneidinger N
BMC Pulm Med. 2024; 24(1):581.
PMID: 39578822
PMC: 11585148.
DOI: 10.1186/s12890-024-03405-y.
Factors associated with sarcopenia among young adults with juvenile idiopathic arthritis: a cross-sectional study.
Kulyk M, Dzhus M
BMC Musculoskelet Disord. 2024; 25(1):923.
PMID: 39558318
PMC: 11572095.
DOI: 10.1186/s12891-024-08051-3.
Efficacy of the cardiac glycoside digoxin as an adjunct to csDMARDs in rheumatoid arthritis patients: a randomized, double-blind, placebo-controlled trial.
El-Mahdy N, Tadros M, El-Masry T, Binsaleh A, Alsubaie N, Alrossies A
Front Pharmacol. 2024; 15:1445708.
PMID: 39498340
PMC: 11532073.
DOI: 10.3389/fphar.2024.1445708.
Correlation of changes in inflammatory and collagen biomarkers with durable guselkumab efficacy through 2 years in participants with active psoriatic arthritis: results from a phase III randomized controlled trial.
Siebert S, Schett G, Raychaudhuri S, Guma M, Chen W, Gao S
Ther Adv Musculoskelet Dis. 2024; 16:1759720X241283536.
PMID: 39493888
PMC: 11528637.
DOI: 10.1177/1759720X241283536.
Structured and prompt treatment of early arthritis in clinical practice leverages window of opportunity and leads to excellent clinical outcomes: an innovative retrospective cohort study.
Teixeira R, da Silva Vieira R, Saavedra M, Polido-Pereira J, Moura R, Alcobia I
Clin Rheumatol. 2024; 43(12):3941-3950.
PMID: 39472411
PMC: 11582134.
DOI: 10.1007/s10067-024-07192-z.
Combining patient-reported outcome measures to screen for active disease in rheumatoid arthritis and psoriatic arthritis.
Looijen A, Snoeck Henkemans S, van der Helm-van Mil A, Welsing P, Koc G, Luime J
RMD Open. 2024; 10(4).
PMID: 39424407
PMC: 11492953.
DOI: 10.1136/rmdopen-2024-004687.
Treat-to-target fixed dose rituximab retreatment versus fixed interval retreatment with disease activity-guided rituximab dose optimisation for patients with rheumatoid arthritis: study protocol for a multicentre randomised controlled superiority....
De Meyst E, Bertrand D, Joly J, Doumen M, Marchal A, Thelissen M
Trials. 2024; 25(1):681.
PMID: 39407334
PMC: 11476693.
DOI: 10.1186/s13063-024-08542-7.
Remote monitoring of rheumatoid arthritis (REMORA): study protocol for a stepped wedge cluster randomized trial and process evaluation of an integrated symptom tracking intervention.
van der Veer S, Griffiths-Jones D, Parkes M, Druce K, Amlani-Hatcher P, Armitage C
Trials. 2024; 25(1):683.
PMID: 39407290
PMC: 11481815.
DOI: 10.1186/s13063-024-08497-9.